TransCode Therapeutics rises on US government grant for cancer therapy

Transcode Therapeutics

05/09/2024 14:02

** Shares of drug developer TransCode Therapeutics  RNAZ.O 
rise 4.3% to 24 cents premarket 
    ** Co says it has been awarded a $2 mln grant by the
National Institutes of Health to support the clinical evaluation
of its experimental therapy TTX-MC138
    ** Funds under the grant are expected to be received over
two years - RNAZ 
    ** TTX-MC138 potentially represents a viable treatment
option for many patients with metastatic cancer- RNAZ
    ** Co says it has recently activated three clinical trial
sites to conduct an early-stage trial of the therapy in advanced
solid tumors
    ** The trial is designed to evaluate of the safety of
TTX-MC138
    ** Up to last close, stock down 96.4% YTD

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))